| 3.82 0.22 (6.11%) | 03-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.01 |
1-year : | 5.85 |
| Resists | First : | 4.28 |
Second : | 5.01 |
| Pivot price | 3.86 |
|||
| Supports | First : | 3.76 |
Second : | 3.43 |
| MAs | MA(5) : | 3.69 |
MA(20) : | 3.82 |
| MA(100) : | 4.12  |
MA(250) : | 2.89 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 22.8 |
D(3) : | 19.6 |
| RSI | RSI(14): 51.4 |
|||
| 52-week | High : | 5.48 | Low : | 1.1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CLLS ] has closed below upper band by 43.0%. Bollinger Bands are 41.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.95 - 3.97 | 3.97 - 3.99 |
| Low: | 3.79 - 3.81 | 3.81 - 3.82 |
| Close: | 3.88 - 3.91 | 3.91 - 3.94 |
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Thu, 08 Jan 2026
Cellectis Sets 2026 Clinical Milestones and Extends Cash Runway Into H2 2027 - TipRanks
Tue, 23 Dec 2025
Cellectis (CLLS) Receives New 'Buy' Rating from Clear Street | C - GuruFocus
Thu, 18 Dec 2025
Cellectis: Showcasing Encouraging Data, But Still Early To Make A Run Like This (CLLS) - Seeking Alpha
Mon, 15 Dec 2025
Cellectis Announces Arbitral Decision in Servier Dispute - TipRanks
Mon, 15 Dec 2025
Cellectis (NASDAQ: CLLS) gets partial UCART19 V1 license termination ruling - Stock Titan
Thu, 11 Dec 2025
Cellectis’ Allogeneic CAR-T Potential Still Justifies A “Buy” (NASDAQ:CLLS) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 73 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 17 (%) |
| Shares Short | 399 (K) |
| Shares Short P.Month | 419 (K) |
| EPS | -0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.38 |
| Profit Margin | -42.9 % |
| Operating Margin | 21.6 % |
| Return on Assets (ttm) | -4.5 % |
| Return on Equity (ttm) | -30.8 % |
| Qtrly Rev. Growth | 105.9 % |
| Gross Profit (p.s.) | 1.13 |
| Sales Per Share | 1.13 |
| EBITDA (p.s.) | -0.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | -11.85 |
| PEG Ratio | 0 |
| Price to Book value | 2.81 |
| Price to Sales | 3.43 |
| Price to Cash Flow | -9.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|